Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer.

Saved in:
Bibliographic Details
Title: Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer.
Authors: Yong L; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China., Liu Y; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, China., Jian WZ; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Cai L; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Bao TY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Liu C; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Gan EZ; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Wang TY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Luo PY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Cao BS; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, China. caobaoshan0711@aliyun.com., Liu W; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China. liuwei0023@bjmu.edu.cn., Zhou TY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. tianyanzhou@bjmu.edu.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2025 Nov; Vol. 46 (11), pp. 3087-3098. Date of Electronic Publication: 2025 Jun 06.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-7254
DOI:10.1038/s41401-025-01573-z